HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: ard.2005.035709v1 ard.2005.035709v2 ard.2005.035709v3 ard.2005.035709v4 65/3/328    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van der Heijde, D Articles by Fatenejad, S Search for Related Content PubMed PubMed Citation Articles by van der Heijde, D Articles by Fatenejad, S

Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial

¹ Rheumatology, University Hospital Maastricht, Maastricht, The Netherlands
² Rheumatology Unit, Department of Medicine, Karolinska Institutet/Karolinska University Hospital, Stockholm, Sweden
³ Global Health Outcomes Assessment, Wyeth Research, Collegeville, PA, USA
⁴ Rheumatology, Hospital General de Guadalajara, Guadalajara, Spain
⁵ Rheumatology, SERVIMED, Lisbon, Portugal
⁶ Centrul de Boli Reumatismale, Bucuresti, Romania
⁷ Global Medical Affairs, Wyeth Research, Collegeville, PA, USA
⁸ Clinical Research and Development, Wyeth Research, Collegeville, PA, USA

Correspondence to:
Correspondence to:
Professor D van der Heijde
Rheumatology, University Hospital Maastricht, Maastricht, The Netherlands; dhe{at}sint.azm.nl

Objective: To compare patient reported measures of function, health related quality of life (QoL), and satisfaction with medication among patients with rheumatoid arthritis (RA) treated with methotrexate (MTX), etanercept, or both for up to 1 year.

Methods: In a 52 week, double blind, clinical trial, patients with active RA were randomised to receive etanercept 25 mg twice weekly, methotrexate up to 20 mg weekly, or combination therapy. The Health Assessment Questionnaire (HAQ) disability index, EuroQoL health status visual analogue scale (EQ-5D VAS), patient global assessment, and patient general health VAS were administered at baseline and weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, and 52. Satisfaction with the medication was compared at 52 weeks.

Results: Of 682 enrolled patients, 522 completed 52 weeks of treatment. Mean improvement from baseline in HAQ score was 0.65, 0.70, and 1.0 for MTX, etanercept, and the combination, respectively. The mean percentage and absolute improvement in the HAQ was significantly higher (p<0.01) for combination therapy than for either of the monotherapies. Combination therapy produced significantly more rapid achievement of HAQ 0.5 sustained for 6 months than either of the monotherapies (p<0.01). Compared with patients receiving monotherapy, those receiving combination therapy achieved a significantly better (p<0.05) health state as measured by the EQ-5D VAS (mean (SD) 63.7 (3.2), 66.8 (3.2), 72.7 (3.1) for MTX, etanercept, and the combination, respectively). Results were similar for other assessments (p<0.01). Patients in combination and etanercept groups were significantly more likely (p<0.0001, p = 0.0009, respectively) to report satisfaction with the medication.

Conclusions: Combination therapy with etanercept and methotrexate improved function, QoL, and satisfaction with the medication significantly more than monotherapy.

Keywords: rheumatoid arthritis; etanercept; methotrexate; functional status; disability; patient outcome assessment; quality of life

This article has been cited by other articles:

				T Karonitsch, D Aletaha, M Boers, S Bombardieri, B Combe, M Dougados, P Emery, D Felson, J Gomez-Reino, E Keystone, et al. Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis Ann Rheum Dis, October 1, 2008; 67(10): 1365 - 1373. [Abstract] [Full Text] [PDF]

				D van der Heijde, R Landewe, R van Vollenhoven, S Fatenejad, and L Klareskog Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial Ann Rheum Dis, September 1, 2008; 67(9): 1267 - 1270. [Abstract] [Full Text] [PDF]

				P L C M van Riel, B Freundlich, D MacPeek, R Pedersen, J R Foehl, A Singh, and on behalf of ADORE study investigators Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial Ann Rheum Dis, August 1, 2008; 67(8): 1104 - 1110. [Abstract] [Full Text] [PDF]

				K. E. Donahue, G. Gartlehner, D. E. Jonas, L. J. Lux, P. Thieda, B. L. Jonas, R. A. Hansen, L. C. Morgan, and K. N. Lohr Systematic Review: Comparative Effectiveness and Harms of Disease-Modifying Medications for Rheumatoid Arthritis Ann Intern Med, January 15, 2008; 148(2): 124 - 134. [Abstract] [Full Text] [PDF]

				M S Heiberg, E Rodevand, K Mikkelsen, C Kaufmann, A Didriksen, P Mowinckel, and T K Kvien Adalimumab and methotrexate is more effective than adalimumab alone in patients with established rheumatoid arthritis: results from a 6-month longitudinal, observational, multicentre study Ann Rheum Dis, October 1, 2006; 65(10): 1379 - 1383. [Abstract] [Full Text] [PDF]

				C. R. Howe, G. C. Gardner, and N. J. Kadel Perioperative medication management for the patient with rheumatoid arthritis. J. Am. Acad. Ortho. Surg., September 1, 2006; 14(9): 544 - 551. [Abstract] [Full Text] [PDF]